These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Sickle cell disease in southwestern Nigeria: assessment of knowledge of primary health care workers and available facilities. Adegoke SA; Akinlosotu MA; Adediji OB; Oyelami OA; Adeodu OO; Adekile AD Trans R Soc Trop Med Hyg; 2018 Feb; 112(2):81-87. PubMed ID: 29579313 [TBL] [Abstract][Full Text] [Related]
4. Barriers and Facilitators of Premarital Genetic Counseling for Sickle Cell Disease in Northern Nigeria. Galadanci AA; Estepp JH; Khan H; Farouk ZL; Caroll Y; Hodges J; Yarima S; Ibrahim UA; Idris IM; Gambo A; Hussaini N; Mukaddas A; DeBaun MR; Galadanci NA J Pediatr Hematol Oncol; 2023 Aug; 45(6):e716-e722. PubMed ID: 37494609 [TBL] [Abstract][Full Text] [Related]
5. Perspectives in Genetics and Sickle Cell Disease Prevention in Africa: Beyond the Preliminary Data from Cameroon. Wonkam A; Ngo Bitoungui VJ; Ngogang J Public Health Genomics; 2015; 18(4):237-41. PubMed ID: 26044545 [TBL] [Abstract][Full Text] [Related]
6. The case for and against initiating either hydroxyurea therapy, blood transfusion therapy or hematopoietic stem cell transplant in asymptomatic children with sickle cell disease. Kassim AA; DeBaun MR Expert Opin Pharmacother; 2014 Feb; 15(3):325-36. PubMed ID: 24392871 [TBL] [Abstract][Full Text] [Related]
7. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. Yawn BP; Buchanan GR; Afenyi-Annan AN; Ballas SK; Hassell KL; James AH; Jordan L; Lanzkron SM; Lottenberg R; Savage WJ; Tanabe PJ; Ware RE; Murad MH; Goldsmith JC; Ortiz E; Fulwood R; Horton A; John-Sowah J JAMA; 2014 Sep; 312(10):1033-48. PubMed ID: 25203083 [TBL] [Abstract][Full Text] [Related]
8. Sickle cell disease: new opportunities and challenges in Africa. Makani J; Ofori-Acquah SF; Nnodu O; Wonkam A; Ohene-Frempong K ScientificWorldJournal; 2013; 2013():193252. PubMed ID: 25143960 [TBL] [Abstract][Full Text] [Related]
9. Sickle cell disease in India. Colah R; Mukherjee M; Ghosh K Curr Opin Hematol; 2014 May; 21(3):215-23. PubMed ID: 24714525 [TBL] [Abstract][Full Text] [Related]
10. Sickle cell disease clinical phenotypes in children from South-Western, Nigeria. Adegoke SA; Adeodu OO; Adekile AD Niger J Clin Pract; 2015; 18(1):95-101. PubMed ID: 25511352 [TBL] [Abstract][Full Text] [Related]
11. Sickle cell disease clinical phenotypes in Nigeria: A preliminary analysis of the Sickle Pan Africa Research Consortium Nigeria database. Isa H; Adegoke S; Madu A; Hassan AA; Ohiaeri C; Chianumba R; Brown B; Okocha E; Ugwu N; Diaku-Akinwumi I; Adeyemo T; Kuliya-Gwarzo A; Dogara L; Lawal H; Tanko Y; Ladu A; Kangiwa U; Ekwem L; Oniyangi S; Wakama T; Umoru D; Olanrewaju O; Akinola N; Nnebe-Agumadu U; Asala S; Adekile A; Olaniyi J; Sangeda R; Sickle Africa Data Coordinating Center SADaCC ; Nnodu O Blood Cells Mol Dis; 2020 Sep; 84():102438. PubMed ID: 32504882 [TBL] [Abstract][Full Text] [Related]
12. Barriers to the use of hydroxyurea in the management of sickle cell disease in Nigeria. Adeyemo TA; Diaku-Akinwunmi IN; Ojewunmi OO; Bolarinwa AB; Adekile AD Hemoglobin; 2019 May; 43(3):188-192. PubMed ID: 31462098 [TBL] [Abstract][Full Text] [Related]
13. Emerging drugs in randomized controlled trials for sickle cell disease: are we on the brink of a new era in research and treatment? Matte A; Cappellini MD; Iolascon A; Enrica F; De Franceschi L Expert Opin Investig Drugs; 2020 Jan; 29(1):23-31. PubMed ID: 31847604 [No Abstract] [Full Text] [Related]
14. Implementation of the therapeutic use of hydroxyurea for sickle cell disease management in resource-constrained settings: a systematic review of adoption, cost and acceptability. Ryan N; Dike L; Ojo T; Vieira D; Nnodu O; Gyamfi J; Peprah E BMJ Open; 2020 Nov; 10(11):e038685. PubMed ID: 33168553 [TBL] [Abstract][Full Text] [Related]
15. Current challenges and new approaches to implementing optimal management of sickle cell disease in sub-Saharan Africa. Ally M; Balandya E Semin Hematol; 2023 Sep; 60(4):192-199. PubMed ID: 37730472 [TBL] [Abstract][Full Text] [Related]
16. Sickle Cell Disease: A Brief Update. Azar S; Wong TE Med Clin North Am; 2017 Mar; 101(2):375-393. PubMed ID: 28189177 [TBL] [Abstract][Full Text] [Related]
17. An overview of sickle cell disease from the socio-demographic triangle - a Nigerian single-institution retrospective study. Nwabuko OC; Onwuchekwa U; Iheji O Pan Afr Med J; 2022; 41():161. PubMed ID: 35655681 [TBL] [Abstract][Full Text] [Related]
18. Current observations on sickle cell genotype in Nigeria. Nduka N; Owhochuku SM; Odike P East Afr Med J; 1993 Oct; 70(10):646-9. PubMed ID: 7514527 [TBL] [Abstract][Full Text] [Related]
19. Real-life experience with hydroxyurea in sickle cell disease: A multicenter study in a cohort of patients with heterogeneous descent. Rigano P; De Franceschi L; Sainati L; Piga A; Piel FB; Cappellini MD; Fidone C; Masera N; Palazzi G; Gianesin B; Forni GL; Blood Cells Mol Dis; 2018 Mar; 69():82-89. PubMed ID: 29107441 [TBL] [Abstract][Full Text] [Related]
20. Newborn Screening for Sickle Cell Disease in Liberia: A Pilot Study. Tubman VN; Marshall R; Jallah W; Guo D; Ma C; Ohene-Frempong K; London WB; Heeney MM Pediatr Blood Cancer; 2016 Apr; 63(4):671-6. PubMed ID: 26739520 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]